文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

印度与东南亚重症患者严重急性肾损伤的流行病学与长期结局

Epidemiology and long-term outcomes of critically ill patients with severe AKI in India and Southeast Asia.
PubMed 文献 · Intensive Care Med · 2025-07-14
一句话结论印度与东南亚24家医院重症AKI 3期患者中,2年MAKE发生率为46.6/100人年(95%CI 42.7-50.6),死亡是主要组分,作者认为需早期识别和密切随访。

该研究基于InSEA-RRT多中心队列,纳入2019年4月至2023年12月印度与东南亚24家医院重症AKI 3期(KDIGO标准)患者2,315例,评估2年主要不良肾脏事件(MAKE,含持续性肾功能障碍、长期透析和全因死亡)。住院期间1,033例(47%)死亡;存活者2年MAKE发生率为46.6/100人年(95%CI 42.7-50.6),其中死亡占32%;2年新发CKD和CKD进展发生率分别为58.6和35.4/100人年。多因素校正显示高龄、男性、既往CKD、恶性肿瘤、心脏相关AKI和AKI后肾功能未恢复是2年MAKE的独立危险因素。作者认为需早期识别和密切随访,并需进一步研究改善长期结局的策略。

要点

  • 重症AKI 3期(KDIGO)患者住院死亡率高:2,315例中1,033例(47%)住院期间死亡。
  • 存活出院者2年MAKE发生率为46.6/100人年(95%CI 42.7-50.6),死亡是MAKE主要组分(32%)。
  • 2年新发CKD发生率为58.6/100人年(95%CI 51.0-67.0),CKD进展为35.4/100人年(95%CI 26.0-47.0)。
  • 2年MAKE独立危险因素包括高龄、男性、既往CKD、恶性肿瘤、心脏相关AKI和AKI后肾功能未恢复。
  • 作者认为早期识别和密切随访此类患者至关重要,并需进一步研究改善长期结局的策略。

适用人群与场景

  • 印度与东南亚24家医院的重症AKI 3期(KDIGO标准)成人患者,纳入时间为2019年4月至2023年12月。
  • 数据来源于印度与东南亚肾脏替代治疗(InSEA-RRT)登记研究,为多中心队列研究。

诊断标准与关键阈值

  • AKI 3期采用KDIGO标准定义。
  • MAKE定义为持续性肾功能障碍、长期透析和入组后2年全因死亡的复合终点。

研究设计与关键结果

  • 多中心队列研究,纳入2,315例重症AKI 3期患者,来自印度与东南亚24家医院。
  • 住院期间1,033例(47%)死亡;存活者2年MAKE发生率为46.6/100人年(95%CI 42.7-50.6),死亡占32%。
  • 2年新发CKD发生率为58.6/100人年(95%CI 51.0-67.0),CKD进展发生率为35.4/100人年(95%CI 26.0-47.0)。
  • 多因素校正模型显示高龄、男性、既往CKD、恶性肿瘤、心脏相关AKI和AKI后肾功能未恢复是2年MAKE的独立危险因素。

证据类型、等级与局限

  • 证据类型:多中心队列研究(印度与东南亚肾脏替代治疗登记研究)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为对重症AKI 3期患者需早期识别并密切随访,以应对高发的2年MAKE和不良长期结局。
  • 作者认为需进一步研究以确定改善该高危人群长期结局的有效策略。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Acute kidney injury (AKI) is associated with significant short-term morbidity and mortality. However, its long-term outcomes, particularly in resource-limited settings, remain poorly understood. This study aimed to evaluate 2-year major adverse kidney events (MAKE) in patients with severe AKI.

METHODS: We analyzed data from the India and Southeast Asia Renal Replacement Therapy (InSEA-RRT) registry, a multicenter cohort study conducted between April 2019 and December 2023 across 24 hospitals in Southeast Asia and India. Critically ill patients with AKI stage 3, as defined by the Kidney Disease Improving Global Outcomes (KDIGO) criteria, were enrolled. The primary outcome was 2-year MAKE, defined as a composite of persistent kidney dysfunction, long-term dialysis, and all-cause mortality at 2 years post-enrollment.

RESULTS: A total of 2,315 patients were enrolled, of whom 1,033 (47%) died during hospitalization. Among surviving patients, the incidence of 2-year MAKE was 46.6 per 100 person-years (95% CI 42.7-50.6). Notably, mortality (32%) was the dominant component of MAKE. The incidence of new chronic kidney disease (CKD) and CKD progression at 2 years post-AKI was 58.6 and 35.4 per 100 person-year (95% CI 51.0-67.0 and 26.0-47.0), respectively. Multivariable-adjusted models identified older age, male sex, preexisting CKD, malignancy, cardiac-associated AKI, and non-recovery of kidney function after AKI as independent risk factors for 2-year MAKE.

CONCLUSIONS: Patients with severe AKI face a high incidence of 2-year MAKE and poor long-term clinical outcomes. Early recognition and close follow-up of these patients are crucial. Further research is needed to identify effective strategies to improve long-term outcomes in this high-risk population.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Tangchitthavorngul S, Lumlertgul N, Peerapornratana S, et al. Epidemiology and long-term outcomes of critically ill patients with severe AKI in India and Southeast Asia. Intensive Care Med. 2025. PMID: 40658243. doi:10.1007/s00134-025-08008-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。